Cargando…

Development of a Population Pharmacokinetic Model of Busulfan in Children and Evaluation of Different Sampling Schedules for Precision Dosing

We develop a population pharmacokinetic model to describe Busulfan pharmacokinetics in paediatric patients and investigate by simulations the impact of various sampling schedules on the calculation of AUC. Seventy-six children had 2 h infusions every 6 h. A two-compartment linear model was found to...

Descripción completa

Detalles Bibliográficos
Autores principales:	Neroutsos, Efthymios, Nalda-Molina, Ricardo, Paisiou, Anna, Zisaki, Kalliopi, Goussetis, Evgenios, Spyridonidis, Alexandros, Kitra, Vasiliki, Grafakos, Stelios, Valsami, Georgia, Dokoumetzidis, Aristides
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2022
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8948694/ https://www.ncbi.nlm.nih.gov/pubmed/35336021 http://dx.doi.org/10.3390/pharmaceutics14030647

Ejemplares similares

Pharmacokinetic Characteristics of Nebulized Colistimethate Sodium Using Two Different Types of Nebulizers in Critically Ill Patients with Ventilator-Associated Respiratory Infections
por: Kyriakoudi, Anna, et al.
Publicado: (2022)

Donepezil Brain and Blood Pharmacokinetic Modeling after Nasal Film and Oral Solution Administration in Mice
por: Kaikousidis, Christos, et al.
Publicado: (2023)

Population Pharmacokinetic Modelling of the Complex Release Kinetics of Octreotide LAR: Defining Sub-Populations by Cluster Analysis
por: Kapralos, Iasonas, et al.
Publicado: (2021)

Pharmacokinetic/Pharmacodynamic Determination of Systemic MIC Breakpoints for Intermittent, Extended, and Continuous Infusion Dosage Regimens of Mecillinam
por: Koumaki, Vasiliki, et al.
Publicado: (2023)

In Silico Dosimetry Study of Tc99m-Tetrofosmin in Children Using a Novel PBPK Model in Humans Built from SPECT Imaging Data
por: Kaikousidis, Christos, et al.
Publicado: (2022)

Implementation of non-linear mixed effects models defined by fractional differential equations
por: Kaikousidis, Christos, et al.
Publicado: (2023)

Effect of pharmacokinetics and pharmacogenomics in adults with allogeneic hematopoietic cell transplantation conditioned with Busulfan
por: Seydoux, Claire, et al.
Publicado: (2023)

Antihypertensive Drugs Metabolism: An Update to Pharmacokinetic Profiles and Computational Approaches
por: Zisaki, Aikaterini, et al.
Publicado: (2015)

Rapid clinical-scale propagation of mesenchymal stem cells using cultures initiated with immunoselected bone marrow CD105(+) cells
por: Spiropoulos, Antonia, et al.
Publicado: (2011)

Candidemia in Children with Malignancies: Report from the Infection Working Group of the Hellenic Society of Pediatric Hematology-Oncology
por: Vasileiou, Eleni, et al.
Publicado: (2020)

Glutathione Transferase Gene Variants Influence Busulfan Pharmacokinetics and Outcome After Myeloablative Conditioning
por: Bremer, Sara, et al.
Publicado: (2015)

Population pharmacokinetic modelling of busulfan and the influence of body composition in paediatric Fanconi anaemia patients
por: van Hoogdalem, Matthijs W., et al.
Publicado: (2020)

Impact of busulfan pharmacokinetics on outcome in adult patients receiving an allogeneic hematopoietic cell transplantation
por: Seydoux, Claire, et al.
Publicado: (2022)

Impact of valproic acid on busulfan pharmacokinetics: In vitro assessment of potential drug-drug interaction
por: Al-Enezi, Bashayer F., et al.
Publicado: (2023)

Characterization and quantitation of busulfan DNA adducts in the blood of patients receiving busulfan therapy
por: Guidolin, Valeria, et al.
Publicado: (2023)

Is there any difference between busulfan-cyclophosphamide and cyclophosphamide-busulfan in patients underwent allogeneic transplantation?
por: Bahçecioğlu, Ömer Faruk, et al.
Publicado: (2021)

Design and Testing of an EHR-Integrated, Busulfan Pharmacokinetic Decision Support Tool for the Point-of-Care Clinician
por: Abdel-Rahman, Susan M., et al.
Publicado: (2016)

Evaluating the Efficacy, Toxicity and Pharmacokinetic Profile of Oral Busulfan in Allogeneic Stem Cell Transplant Patients
por: Salvaris, Ross, et al.
Publicado: (2022)

Pulmonary hypertension associated with busulfan
por: Hagenburg, Jean, et al.
Publicado: (2021)

Population pharmacokinetics of oral high-dose busulfan in adult patients undergoing hematopoietic stem cell transplantation
por: Hadjibabaie, M., et al.
Publicado: (2011)

A Simple Dosing Scheme for Intravenous Busulfan Based on Retrospective Population Pharmacokinetic Analysis in Korean Patients
por: Choe, Sangmin, et al.
Publicado: (2012)

The Correlation Between Busulfan Exposure and Clinical Outcomes in Chinese Pediatric Patients: A Population Pharmacokinetic Study
por: Du, Xiaohuan, et al.
Publicado: (2022)

Population Pharmacokinetics of Busulfan and Its Metabolite Sulfolane in Patients with Myelofibrosis Undergoing Hematopoietic Stem Cell Transplantation
por: Dadkhah, Adrin, et al.
Publicado: (2022)

External Evaluation of Population Pharmacokinetic Models of Busulfan in Chinese Adult Hematopoietic Stem Cell Transplantation Recipients
por: Huang, Huiping, et al.
Publicado: (2022)

Population pharmacokinetic model for once‐daily intravenous busulfan in pediatric subjects describing time‐associated clearance
por: Lawson, Rachael, et al.
Publicado: (2022)

Fludarabine with pharmacokinetically-guided IV busulfan is superior to fixed-dose delivery in pretransplant conditioning of AML/MDS patients
por: Andersson, Borje S., et al.
Publicado: (2016)

Optimization of Busulfan Dosing Regimen in Pediatric Patients Using a Population Pharmacokinetic Model Incorporating GST Mutations
por: Yuan, Jinjie, et al.
Publicado: (2021)

Implementation and Cross-Validation of a Pharmacokinetic Model for Precision Dosing of Busulfan in Hematopoietic Stem Cell Transplanted Children
por: Goutelle, Sylvain, et al.
Publicado: (2022)

Thiotepa-busulfan-fludarabine compared to busulfan-fludarabine for sibling and unrelated donor transplant in acute myeloid leukemia in first remission
por: Saraceni, Francesco, et al.
Publicado: (2017)

Adverse Effects of Busulfan Plus Cyclophosphamide versus Busulfan Plus Fludarabine as Conditioning Regimens for Allogeneic Bone Marrow Transplantation
por: Mehdizadeh, Mahshid, et al.
Publicado: (2021)

Influence of glutathione S-transferase gene polymorphisms on busulfan pharmacokinetics and outcome of hematopoietic stem-cell transplantation in thalassemia pediatric patients
por: Ansari, M, et al.
Publicado: (2016)

Pharmacokinetics-adapted Busulfan-based myeloablative conditioning before unrelated umbilical cord blood transplantation for myeloid malignancies in children
por: Benadiba, Joy, et al.
Publicado: (2018)

Melatonin and Testicular Damage in Busulfan Treated Mice
por: Mirhoseini, Mehri, et al.
Publicado: (2014)

Systemic Histopathology of Infant Rats Exposed to Busulfan
por: Ohira, Toko, et al.
Publicado: (2014)

Busulfan-cyclophosphamide versus cyclophosphamide-busulfan as conditioning regimen before allogeneic hematopoietic cell transplantation: a prospective randomized trial
por: Seydoux, Claire, et al.
Publicado: (2020)

Population Pharmacokinetic Model of Adalimumab Based on Prior Information Using Real World Data
por: Marquez-Megias, Silvia, et al.
Publicado: (2023)

Is a third SARS‐CoV‐2 vaccine dose efficient in allogeneic haematopoietic cell transplant recipients?
por: Spyridonidis, Alexandros
Publicado: (2022)

Dose Schedule Optimization and the Pharmacokinetic Driver of Neutropenia
por: Patel, Mayankbhai, et al.
Publicado: (2014)

Precision dosing of intravenous busulfan in pediatric hematopoietic stem cell transplantation: Results from a multicenter population pharmacokinetic study
por: Ben Hassine, Khalil, et al.
Publicado: (2021)

Correlation of Immunoglobulins and Lymphocytes Levels With the Clinical and Microbiological Response of Septic Patients With Gram-Negative Bacteremia
por: Aretha, Diamanto, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_5bkfod1dqeo24e7tpdnte37opi